Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 2/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6178258 | 0.80 | MALT1 (0.51) | CA12CA1DRD2KDM4A | |
| SCHEMBL6969037 | 0.78 | TDP1 (0.47) | CA12CA1DRD2 | |
| SCHEMBL6962221 | 0.78 | STK17B (0.47) | MEN1KMT2AGAACA12CA1 | |
| SCHEMBL10852799 | 0.78 | HPGD (0.47) | LMNAPOLBMEN1NPC1RAB9A | |
| SCHEMBL14634232 | 0.77 | LCK (0.39) | LMNAPOLBNPC1RAB9ACA12 | |
| SCHEMBL11316710 | 0.76 | HSD17B10 (0.45) | POLBMEN1NPC1RAB9AKMT2A | |
| SCHEMBL9599428 | 0.76 | ALDH1A1 (0.47) | LMNAMEN1RAB9AKMT2AGAA | |
| SCHEMBL7403603 | 0.76 | LCK (0.41) | LMNAPOLBCA12CA1NAMPT | |
| SCHEMBL1192082 | 0.76 | MEN1 (0.36) | LMNAPOLBMEN1NPC1RAB9A | |
| SCHEMBL7663505 | 0.76 | ATM (0.42) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3050873-B1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-09-13 | — | — | EP | claimed |
| EP-3050873-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-08-03 | — | — | EP | claimed |
| EP-2651893-B1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-03-30 | — | — | EP | claimed |
| EP-2651893-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-23 | — | — | EP | claimed |
| US-8450367-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2013-05-28 | — | — | US | claimed |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | claimed |
| WO-2012082566-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | claimed |
| EP-3050873-B1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-9663460-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170050925-A9 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2017-02-23 | — | — | US | disclosed |
| EP-3050873-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2651893-B1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-20140378492-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2014-12-25 | — | — | US | disclosed |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8143268-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-03-27 | — | — | US | disclosed |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-01-13 | — | — | US | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | LMNA 2777/4885POLB 679/4885MEN1 1774/4885 |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | LMNA 1854/4885POLB 3626/4885MEN1 203/4885 |
| US-20140378492-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | LMNA 4884/4885POLB 3493/4885MEN1 4826/4885 |
| US-20170050925-A9 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | LMNA 4884/4885POLB 3493/4885MEN1 4826/4885 |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | LMNA 4884/4885POLB 3493/4885MEN1 4826/4885 |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | LMNA 2777/4885POLB 679/4885MEN1 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.